STAAR Surgical (STAA) Getting Somewhat Positive Press Coverage, Report Finds

Media coverage about STAAR Surgical (NASDAQ:STAA) has been trending somewhat positive on Wednesday, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. STAAR Surgical earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 45.3326654419489 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Several equities analysts recently weighed in on the company. Benchmark reiterated a “buy” rating and set a $21.00 target price on shares of STAAR Surgical in a research report on Monday, November 20th. Canaccord Genuity increased their target price on STAAR Surgical from $17.50 to $20.00 and gave the stock a “buy” rating in a research report on Friday, November 17th. Zacks Investment Research downgraded STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. BidaskClub upgraded STAAR Surgical from a “sell” rating to a “hold” rating in a research note on Saturday, August 19th. Finally, TheStreet upgraded STAAR Surgical from a “d+” rating to a “c” rating in a research note on Tuesday, August 15th. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. STAAR Surgical currently has an average rating of “Buy” and an average price target of $17.67.

Shares of STAAR Surgical (NASDAQ:STAA) opened at $16.00 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.72 and a current ratio of 2.24. STAAR Surgical has a 12 month low of $8.95 and a 12 month high of $17.60.

In other news, VP Keith Holliday sold 6,000 shares of the stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $16.65, for a total value of $99,900.00. Following the completion of the sale, the vice president now owns 45,969 shares in the company, valued at $765,383.85. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 3.40% of the stock is currently owned by company insiders.

WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at

STAAR Surgical Company Profile

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.

Insider Buying and Selling by Quarter for STAAR Surgical (NASDAQ:STAA)

What are top analysts saying about STAAR Surgical? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for STAAR Surgical and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit